老年癌症患者综合药学干预的临床影响与成本节约分析
研究纳入201例75岁以上癌症住院患者,评估RECAP综合药学干预(入院和出院时药物重整与审查、提供优化建议、出院教育和信息共享)的效果。结果显示70.9%患者入院时存在需优化的药物相关问题,70.8%的药学建议被采纳,半数解决的DRPs有临床意义,但出院时多重用药率未降低;成本分析显示每投入1美元可避免7.2美元成本,估计净收益354,822美元。
要点
- 入院时70.9%患者存在需优化的DRPs,平均1.7个/人;出院时47.7%,平均0.9个/人。
- 70.8%的药学建议被采纳,入院和出院时分别纠正1.2和0.7个DRP/人,半数有临床意义。
- 干预未降低出院时多重用药率,但成本节约显著,每投入1美元避免7.2美元成本。
核心结论
- RECAP综合药学干预显著减少住院老年癌症患者的药物相关问题,且具有成本节约效益。
研究设计与样本
- 研究纳入2019年1月至2020年8月期间201例年龄≥75岁、收入肿瘤或老年病房的癌症患者,中位年龄80岁(范围75-97岁),68.7%为实体瘤。
主要发现
- 入院时70.9%患者存在需优化的DRPs(平均1.7个/患者),出院时47.7%(平均0.9个/患者)。
- 70.8%的药学建议被处方者采纳,入院时纠正1.2个DRP/患者,出院时纠正0.7个DRP/患者。
- 半数已解决的DRPs被专家小组评定为有临床意义。
- 出院时多重用药率未降低。
- 成本比较显示每投入1美元可避免7.2美元成本,估计总净收益354,822美元(平均每患者1,766美元)。
临床怎么用
- 可在老年癌症患者入院和出院时实施综合药学干预,包括药物重整、审查、优化建议、患者教育和信息共享,以减少DRPs并节约成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital admission and discharge are at high risk of drug-related problems (DRPs) in older patients with cancer. This study aimed to assess the clinical and economic impact of a comprehensive pharmaceutical care intervention (RECAP) to optimize drug therapy in patients with cancer ≥75 years admitted to oncology or geriatric wards. METHOD: RECAP intervention was defined as follows: at admission and discharge, hospital pharmacists conducted comprehensive medication reconciliation and review, identified relevant DRPs and provided optimization recommendations to prescribers; at discharge, pharmacists also provided patient education and shared information with primary care providers. The impact of the intervention was assessed by the rate of implementation of recommendations by the prescribers and the evolution of polypharmacy rate; a peer review of the clinical significance of DRPs was performed by an expert panel of geriatric oncologists and pharmacists. A cost saving analysis compared cost avoided through resolution of DRPs to cost of pharmacist's time. RESULTS: From January 2019 and August 2020, 201 patients were included (median age 80 [75-97] years), 68.7% with solid tumors. DRPs requiring optimization were identified in 70.9% of patients at admission (mean 1.7 DRP/patient) and 47.7% at discharge (0.9 DRP/patient). Most pharmacist recommendations (70.8%) were followed by prescribers, allowing the correction of 1.2 DRP/patient at admission and 0.7 DRP/patient at discharge. Half of resolved DRPs were rated as clinically significant. However, polypharmacy rate was not reduced at discharge. Cost comparison showed $7.2 avoided for $1 invested, with an estimated total net benefit of $354,822 (mean $1766 per patient). CONCLUSIONS: The RECAP model significantly reduces DRPs in hospitalized older patients with cancer. The model was cost saving, confirming the value of implementing it in routine practice.
引用
- Herledan C, Falandry C, Huot L, et al. Clinical impact and cost-saving analysis of a comprehensive pharmaceutical care intervention in older patients with cancer. J Am Geriatr Soc. 2023. PMID: 37818698. doi:10.1111/jgs.18585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。